Facharzt FMH Medizinische Onkologie - independent subject foundations cheat sheet

Combine diagnosis, stage, biology and treatment intent before comparing regimens.

A predictive marker has a specific disease and treatment context.

Do not confuse maintenance after disease control with treatment after progression.

Use actual organ function, prior treatment and patient priorities in multidisciplinary reasoning.

Differentiate drug mechanism, rescue and drug elimination.

An antibody-drug conjugate has a specific target, linker and payload.

Interpret resistance and biomarkers within the actual tumor context.

A correct formula result does not independently validate every input or prescription.

Integrate morphology, phenotype and molecular evidence instead of classifying from a count alone.

Treat suspected APL and other urgent complications through the appropriate coordinated pathway.

Distinguish a diagnosis from an indication to begin treatment.

Keep transplant type, cellular target and characteristic toxicities separate.

Separate tumor-related, treatment-related and competing causes of deterioration.

Use validated risk tools only with their full clinical conditions.

Severity and involved organ change immune-toxicity management.

A studied intervention is not automatically an established preventive treatment.

Palliative support can coexist with disease-directed treatment.

Treat opioid conversion and symptom decisions as individualized clinical tasks.

Distinguish hazard, cumulative risk and absolute treatment effect.

Check endpoints, uncertainty and study-population applicability before transferring a trial result.